Trusted Resource for Clinical Trials, Protocols & Progress
The IB provides investigators with comprehensive knowledge about the investigational product, including pharmacology, toxicology, efficacy, and safety findings. It enables the responsible conduct of clinical trials and is mandated by international guidelines, including USFDA and ICH E6 (R2) Good Clinical Practice (GCP).
Click to read the full article.
Distributing the IB to all clinical trial stakeholders—investigators, ethics committees (ECs), regulatory authorities, CROs, and sponsors—ensures everyone involved has the latest scientific and safety data. Controlled distribution:
Click to read the full article.
The IB is a living document that summarizes nonclinical and clinical data, including safety, pharmacology, dosing, and known risks. Review of this document ensures investigators can:
Click to read the full article.
Templates ensure uniformity in content structure, which facilitates easier review, comparison, and regulatory submission. Benefits include:
Click to read the full article.
IBs must provide comprehensive data to support investigator understanding, but the content must also be:
Click to read the full article.
The PK section of the IB supports:
Click to read the full article.
Compliance with the ICH E3 guideline is essential because it:
Click to read the full article.
Data integrity is vital, but even the best data loses value if poorly presented. Good data presentation helps in:
Click to read the full article.
The SAP outlines the statistical methodology for a clinical study. It defines how endpoints will be analyzed, what statistical models will be applied, and which TLFs will be generated. TLFs are the visual outputs of the SAP, providing a summary or listing of the analyzed data. The CSR, in turn, is the narrative that describes and interprets these results.
Click to read the full article.
Before diving into individual data points, plan the discussion using a structured strategy:
Click to read the full article.
